Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Spartalizumab + Lacnotuzumab in Gastric Cancer
NCT03694977Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab and lacnotuzumab in gastric cancer (GC), sponsored by Seoul National University Hospital. Primary endpoint: Identification of potential biomarkers of MCS110 in combination with PDR001 at 3 weeks. Status: unknown.
02
Drugs
spartalizumablacnotuzumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03694977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694977.